Illumina VeriSeq NIPT Solution v2
Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version expands the range of chromosomal and sub-chromosomal conditions associated with birth defects that laboratories can screen for. The assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. It is available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.